Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries
Abstract:
The receptor tyrosine kinase inhibitor cabozantinib (XL184, BMS-907351 Cometriq) has displayed impressive clinical activity against several indications, culminating in its recent approval for medullary thyroid cancer. Among malignancies with tropism for the bone (prostate, breast), one striking feature of early clinical reports about this drug has been the rapid and complete resolution of bone scans, a phenomenon almost never observed even among therapies already shown to confer survival benefit. In castration-resistant prostate cancer, not all conventional response indicators change as dramatically posttreatment, raising the possibility that cabozantinib may impair the ability of bone-seeking radionuclides to integrate within the remodeling bone. To test this hypothesis, we surgically induced bone remodeling via physical insult in non-tumor-bearing mice and performed 18F-sodium fluoride (18F-NaF) positron emission tomographic (PET) and technetium 99m-methylene diphosphonate (99mTc-MDP) single-photon emission computed tomographic (SPECT) scans pre- and posttreatment with cabozantinib and related inhibitors. A consistent reduction in the accumulation of either radiotracer at the site of bone remodeling was observed in animals treated with cabozantinib. Given that cabozantinib is known to inhibit several receptor tyrosine kinases, we drugged animals with various permutations of more selective inhibitors to attempt to refine the molecular basis of bone scan resolution. Neither the vascular endothelial growth factor receptor (VEGFR) inhibitor axitinib, the MET inhibitor crizotinib, nor the combination was capable of inhibiting 18F-NaF accumulation at known bioactive doses. In summary, although the mechanism by which cabozantinib suppresses radionuclide incorporation into foci undergoing bone remodeling remains unknown, that this phenomenon occurs in tumor-naïve models indicates that caution should be exercised in interpreting the clinical significance of this event.
Insights
Cabozantinib causes bone scans to appear normal by reducing radiotracer uptake in bone, even without tumors. The exact mechanism remains unclear, warranting caution in interpreting these imaging results.
Area of Science:
- Oncology
- Radiology
- Pharmacology
Background:
- Cabozantinib is a receptor tyrosine kinase inhibitor with clinical activity in various cancers.
- Rapid resolution of bone scans is a notable observation in patients treated with cabozantinib for bone-metastatic cancers.
- This phenomenon suggests a potential interference with bone-seeking radiotracer uptake.
Purpose of the Study:
- To investigate the effect of cabozantinib on radiotracer accumulation in bone remodeling.
- To explore the underlying molecular mechanisms of cabozantinib-induced bone scan resolution.
Main Methods:
- Surgically induced bone remodeling in non-tumor-bearing mice.
- 18F-sodium fluoride (18F-NaF) PET and 99mTc-methylene diphosphonate (99mTc-MDP) SPECT imaging before and after cabozantinib treatment.
- Administration of selective receptor tyrosine kinase inhibitors (axitinib, crizotinib) to assess their impact on radiotracer uptake.
Main Results:
- Cabozantinib treatment consistently reduced radiotracer accumulation at sites of bone remodeling.
- Neither VEGFR inhibitor axitinib nor MET inhibitor crizotinib inhibited 18F-NaF accumulation at bioactive doses.
- The observed effect occurred in tumor-naïve models.
Conclusions:
- Cabozantinib significantly reduces radiotracer uptake in remodeling bone, independent of tumor presence.
- The precise mechanism by which cabozantinib affects radionuclide incorporation into bone remains to be elucidated.
- Clinical interpretation of bone scan resolution in patients treated with cabozantinib requires careful consideration.
More Related Videos
06:53Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone
Published on: September 9, 2020
11:31Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer
Published on: May 20, 2016
